Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium
LA JOLLA, Calif., July 3, 2018 /PRNewswire/ -- Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, today announces its sponsorship of the Young Investigator Award at the 28th Annual Symposium of the International Cannabinoid Research Society, being held June 30-July 5, 2018 in Leiden, Netherlands.
"The Young Investigator Award is a unique opportunity to identify and showcase researchers who have demonstrated dedication to endocannabinoid system research. We are extremely pleased to be an integral part of the conference as the sole sponsor of the award for the next five years," said Greg Gorgas, CEO of Artelo Biosciences. "The impact of the award for our company is more than just straight sponsorship. Artelo entered into mutually beneficial research collaborations with the 2016 winner Dr. Saoirse O'Sullivan from the University of Nottingham, UK, and with one of last year's recipient's Dr. Martin Kaczocha from Stony Brook University, New York, providing Artelo access to the latest cutting edge and emerging science."
Dr. Kaczocha is a leading research collaborator with ART26.12, a highly selective and highly potent fatty acid binding protein 5 (FABP5) inhibitor exclusively licensed to Artelo. Dr. Kaczocha's presentation on July 2, 2018 at the ICRS Annual Symposium, "Targeting FABP5 to Treat Pain, Inflammation, and Cancer," will discuss the distinct functions of FABP5 in endocannabinoid signaling and will feature new research on the therapeutic potential of targeting FABP5 to treat metastatic prostate cancer.
About Artelo Biosciences
Artelo Biosciences, Inc. (OTCQB: ARTL) is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Through an exclusive agreement and in collaboration with The Research Foundation of the State University of New York Stony Brook, Artelo is developing a Fatty Acid Binding Protein 5 (FABP5) inhibitor to modulate the endocannabinoid system for the treatment of cancer, inflammation, and pain. Fatty Acid Binding Proteins have been identified as intracellular transporters for the endocannabinoid anandamide (AEA), a neurotransmitter produced in the brain that binds to CB1 and CB2 receptors. Inhibition of FABP5 will lead to higher levels of AEA and may have significant potential in treating pain. Additionally, FABP5 and PPARß/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. Artelo is working with Stony Brook University to optimize a FABP5 inhibitor for the treatment of breast and prostate cancers.
About the International Cannabinoid Research Society
The International Cannabinoid Research Society is the premier global scientific association dedicated to the scientific research in all fields of the cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. Interested parties may follow @ICRS_Society on Twitter and use #ICRS2018 for the latest meeting updates.
Forward Looking Statements:
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
View original content with multimedia:http://www.prnewswire.com/news-releases/artelo-biosciences-announces-five-year-commitment-to-sponsor-the-young-investigator-award-at-the-international-cannabinoid-research-society-annual-symposium-300675669.html
SOURCE Artelo Biosciences, Inc.
Released July 3, 2018